Economic Impact of VTE
A number of studies have estimated the economic burden of VTE,[33–37] and it has been noted that any type of prophylaxis saves costs compared with no prophylaxis. The costs of DVT were found to vary depending on the occurrence of complications. One study found that the mean 6-month treatment costs for inpatient management ranged from US$3906 to US$17,168, depending on complication status. For outpatient management in the 6 months after DVT, costs ranged from US$2394 to US$3369, depending on the frequency of LMWH injection and the need for professional assistance. However, compared with warfarin, extended prophylaxis with LMWH has been found to be cost effective. Studies of the economic consequences of VTE after major orthopedic surgery have yielded a number of estimates. A study using data from a large healthcare claims database calculated much higher in-hospital mean billed charges for the index admission after THA: US$36,705 in patients with no VTE, US$62,558 in patients with in-hospital VTE and US$34,970 for a post-discharge VTE. Similarly, costs after TKA were US$35,601 in patients with no VTE, US$44,898 in patients with in-hospital VTE and US$31,774 for a post-discharge VTE.
Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(3):299-306. © 2011 Expert Reviews Ltd.
Cite this: Economic Impact of Venous Thromboembolism After Hip and Knee Arthroplasty - Medscape - Jun 01, 2011.